EBV CAR-T Cells for Nasopharyngeal Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

CAR-T Cell Injection

intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。

DRUG

Fludarabine

Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)

DRUG

cyclophosphamide

250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
collaborator

Guangzhou Bioresette Biomedical Technology Co., Ltd.

INDUSTRY

lead

The Affiliated Hospital of Xuzhou Medical University

OTHER